How do we treat life-threatening anemia in a Jehovah's Witness patient?

Transfusion

Volumn 54, Issue 12, 2014, Pages 3026-3034

  Posluszny, Joseph A ^a   Napolitano, Lena M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; ERYTHROPOIETIN; FOLIC ACID; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON; POLYMERIZED HEMOGLOBIN; ANTIANEMIC AGENT; BLOOD SUBSTITUTE;

ANEMIA; ARTICLE; CLINICAL PROTOCOL; CYANOCOBALAMIN DEFICIENCY; DISEASE SEVERITY; ERYTHROCYTE; ERYTHROPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON STORAGE; IRON THERAPY; JEHOVAH'S WITNESS; LIFE THREATENING ANEMIA; MORTALITY; OUTCOME ASSESSMENT; PHLEBOTOMY; THERAPY DELAY; ALGORITHM; BLOOD; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATIENT PARTICIPATION; PSYCHOLOGY;

ADMINISTRATION, INTRAVENOUS; ALGORITHMS; ANEMIA; BLOOD SUBSTITUTES; ERYTHROPOIESIS; HEMATINICS; HEMOGLOBINS; HUMANS; IRON; JEHOVAH'S WITNESSES; PATIENT PARTICIPATION;

EID: 84916605813     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12888     Document Type: Article

References (50)

1. Bodnaruk ZM, Wong CJ, Thomas MJ,. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 2004; 18: 105-116.
2. Gannon CJ, Napolitano LM,. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med 2002; 30: 1893-1895.
3. Carson JL, Noveck H, Berlin JA, et al. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42: 812-818.
4. Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion. Transfusion 2014; 54: 2688-2695.
5. de Araújo Azi LM, Lopes FM, Garcia LV,. Postoperative management of severe acute anemia in a Jehovah's Witness. Transfusion 2014; 54: 1153-1157.
6. Tobian AA, Ness PM, Noveck H, et al. Time course and etiology of death in patients with severe anemia. Transfusion 2009; 49: 1395-1399.
7. Beliaev AM, Marshall RJ, Smith W, et al. Mortality risk stratification in severely anaemic Jehovah's Witness patients. Intern Med J 2012; 42: e1-3.
8. Beliaev AM, Marshall RJ, Smith W, et al. Treatment monitoring and mortality risk adjustment in anaemic Jehovah's Witnesses. ANZ J Surg 2013; 83: 161-164.
9. Elliott S, Pham E, Macdougall IC,. Erythropoietins: a common mechanism of action. Exp Hematol 2008; 36: 1573-1584.
10. Imamura R, Moriyama T, Isaka Y, et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007; 83: 1371-1379.
11. Lundby C, Olsen NV,. Effects of recombinant human erythropoietin in normal humans. J Physiol 2011; 589 (Pt 6): 1265-1271.
12. Goodnough LT, Marcus RE,. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128-133.
13. Zarychanski R, Turgeon AF, McIntyre L, et al. Erythropoietin receptor agonists in critically ill patients. A meta-analysis of randomized controlled trials. CMAJ 2007; 177: 725-734.
14. Corwin HL, Gettinger A, Fabian TC, et al.; EPO Critical Care Trials Group. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976.
15. Elliott J, Mishler D, Agarwal R,. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009; 16: 94-100.
16. Charles A, Purtill M, Napolitano LM,. Recombinant human erythropoietin in severe anaemia: issues of dosing and duration. Anaesth Intensive Care 2006; 34: 793-796.
17. Arroliga AC, Guntupalli KK, Beaver JS, et al. Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med 2009; 37: 1299-1307.
18. Napolitano LM,. Epoetin alfa in the critically ill: what dose? Which route? Crit Care Med 2009; 37: 1501-1503.
19. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, et al. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000; 28: 2773-2778.
20. Urrechaga E, Borque L, Escanero JF,. Biomarkers of hypochromia: the contemporary assessment of iron status and erythropoiesis. Biomed Res Int 2013; 2013: 603786.
21. Barsun A, Sen S, Palmieri TL, et al. Reducing postburn injury anemia in a Jehovah's Witness patient. J Burn Care Res 2014; 35: e258-261.
22. Lorentzen K, Kjær B, Jørgensen J,. Supportive treatment of severe anaemia in a Jehovah's Witness with severe trauma. Blood Transfus 2013; 11: 452-453.
23. Vaziri K, Roland JC, Robinson LL, et al. Extreme anemia in an injured Jehovah's Witness: a test of our understanding of the physiology of severe anemia and the threshold for blood transfusion. J Trauma 2009; 67: E11-13.
24. Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia-systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013; 52: 18-29.
25. Harwin SF, Pivec R, Johnson AJ, et al. Revision total hip arthroplasty in Jehovah's Witnesses. Orthopedics 2012; 35: e1145-1151.
26. Sihler KC, Napolitano LM,. Anemia of inflammation in critically ill patients. J Intensive Care Med 2008; 23: 295-302.
27. ClinicalTrials.gov. Expanded access study of HBOC-201 (Hemopure) for the treatment of life-threatening anemia. 2014. [cited 2014 May 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT01881503.
28. ClinicalTrials.gov. An assessment of the safety and pharmacokinetics of ascending doses of Sanguinate in healthy volunteers. NCT01847222; 2013. [cited 2014 May 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT01847222.
29. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008; 64: 1484-1497.
30. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008; 299: 2304-2312.
31. Fergusson DA, McIntyre L,. The future of clinical trials evaluating blood substitutes. Editorial. JAMA 2008; 299: 2324-2326.
32. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-1562.
33. Gerber DR,. Transfusion of packed red blood cells in patients with ischemic heart disease. Crit Care Med 2008; 36: 1068-1074.
34. Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010; 304: 1559-1567.
35. Weiskopf RB,. Hemoglobin-based oxygen carriers: compassionate use and compassionate clinical trials. Anesth Analg 2010; 110: 659-662.
36. Donahue LL, Shapira I, Shander A, et al. Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: a case report and review of literature. Transfusion 2010; 50: 1561-1567.
37. Lundy JB, Lewis CJ, Cancio LC, et al. Experience with the use of Hemopure in the care of a massively burned adult. Int J Burns Trauma 2014; 4: 45-48.
38. Fitzgerald MC, Chan JY, Ross AW, et al. A synthetic haemoglobin-based oxygen carrier and the reversal of cardiac hypoxia secondary to severe anaemia following trauma. Med J Aust 2011; 194: 471-473.
39. Jordan SD, Alexander E,. Bovine hemoglobin: a nontraditional approach to the management of acute anemia in a Jehovah's Witness patient with autoimmune hemolytic anemia. J Pharm Pract 2013; 26: 257-260.
40. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after the use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010; 110: 685-693.
41. Lippi G, Franchini M, Favaloro EJ,. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost 2010; 36: 537-549.
42. Chavez-MacGregor M, Zhao H, Fang S, et al. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer 2011; 117: 3641-3649.
43. US Food and Drug Administration. Physician request for an individual patient IND under expanded access for non-emergency or emergency use. 2013. [cited 2014 Sep 19]. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/InvestigationalNewDrugINDApplication/ucm107434.htm.
44. Sun CC, Vaja V, Babitt JL, et al. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol 2012; 87: 392-400.
45. Ganz T, Nemeth E,. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011; 2011: 538-542.
46. Sihler KC, Raghavendran K, Westerman M, et al. Hepcidin in trauma: linking injury, inflammation, and anemia. J Trauma 2010; 69: 831-837.
47. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010; 95: 505-508.
48. Schwoebel F, van Eijk LT, Zboralski D, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 2013; 121: 2311-2315.
49. Hohlbaum A, Gille H, Christian J, et al. Iron mobilization and pharmacodynamics marker measurements in non-human primates following administration of PRS-080, a novel and highly specific anti-hepcidin therapeutic [abstract]. Am J Hematol 2013; 5: E41.
50. Fung E, Nemeth E,. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013; 98: 1667-1676.